Obesity diminishes response to immunotherapy in kidney cancer

In this study, the researchers looked at the interaction between obesity and outcomes in patients taking immune checkpoint inhibitors (anti-PD-1 immunotherapy, e.g. nivolumab, pembrolizumab) for the treatment of renal cell carcinoma (RCC). Seventy-two (72) patients with metastatic RCC were treated with anti–PD-1 immunotherapy (none had been treated with immunotherapy before). Obese patients had poorer progression-free […]

read more

ASCO 2020: Factors influencing outcomes in kidney cancer treated with immunotherapy

A study presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program has identified several features of kidney cancer tumours that influence their response to immune checkpoint inhibitors, such as nivolumab and pembrolizumab. The research was conducted at the Dana-Farber Cancer Institute in America and is published in the journal, Nature Medicine. […]

read more

The future of immunotherapy-based combinations for metastatic kidney cancer

The past decade or so has seen the development of multiple targeted therapies for metastatic renal cell carcinoma (RCC), such as vascular endothelial growth factor (VEGF) inhibitors and inhibitors of the mammalian target of rapamycin (mTOR) pathway. Most recently, immune checkpoint inhibitors have been shown to have excellent clinical efficacy. Although patients are living longer, […]

read more

Combination PD-1 and PD-L1 inhibitors for kidney cancer are no more beneficial than PD-1 inhibitor alone

A recent phase II clinical trial has shown that combined use of a PD-1 inhibitor and a PD-L1 inhibitor proved no more beneficial than anti-PD-1 treatment alone in metastatic renal cell carcinoma (RCC) patients who had already been treated with targeted therapy. There was no significant difference in the primary endpoint of the study, which […]

read more

PD-L1 can be used to predict the likely course of kidney cancer

A recently published study evaluated the role of programmed-death receptor ligand (PD-L1) as an indicator of the likely course (prognosis) of clear cell renal cell carcinoma (RCC). A total of 738 patients were included in the study and followed for around 34 months. The presence of PD-L1 and PD-1 receptors in the tumour cells was […]

read more

PD-1 and CTLA-4 as biomarkers for survival in kidney cancer

A recent study published in Journal of Clinical Medicine last month provides evidence for the expression of PD-1 and CTLA-4 receptors on white blood cells (tumour-infiltrating mononuclear cells) to be associated with a worse overall survival in patient with renal cell carcinoma (RCC). The combination of PD-1 and CTLA-4 expression in tumour-infiltrating mononuclear cells might […]

read more

PD-1, PD-L1 and PD-L2 levels differ between patients

In a recent study, published in BMC Cancer last month, it was reported that the levels of the programmed cell death proteins PD-1, PD-L1 and PD-L2 varied between primary tumour, metastases and site of metastases. For example, PD-L1 was higher in metastatic tumours compared with primary tumours, and PD-1 expression was 65.3% in lung/lymph metastases […]

read more

Clinical significance of PD-1 and PD-L1 receptors in kidney cancer

A recent study, published in Cancer Science this month, suggests that PD-1 and PD-L1 expression by immune cells in kidney cancer tumours is involved in resistance to treatment, i.e. part of the reason why tumours stop responding to treatment. The researchers suggest that treatment with immune checkpoint inhibitors may be a promising therapeutic strategy for […]

read more

Potential biomarker for kidney cancer survival identified

A recent paper from researchers in China and published in Dove Medical Press investigated whether immune cells called CD8+ T cells and the PD-1/PD-L1 pathway impact overall survival in people with metastatic renal cell carcinoma (mRCC) who are treated with tyrosine kinase inhibitors (TKIs). The findings from the study suggest that large quantities of CD8+ T […]

read more
Showing all 9 results
  TOP